文献速递精神分裂症与精神病性障碍

临床高危精神病个体血清NMDAR自身抗体的临床、认知与神经解剖关联

Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis.
PubMed 文献 · Mol Psychiatry · 2020-10-19

该病例对照研究检测254例临床高危(CHR)个体和116名健康志愿者的血清神经元自身抗体,发现CHR组与对照组血清阳性率无显著差异(8.3% vs 5.2%)。在CHR组内,NMDAR抗体阳性与当前抑郁水平更高、言语记忆表现更差、IQ更低相关,且抗体状态与随访功能较差及杏仁核体积较大相关。NMDAR抗体并未在后来转为精神病者中更常见。

要点

  • CHR个体神经元自身抗体血清阳性率与健康对照无显著差异(8.3% vs 5.2%)。
  • CHR组内NMDAR抗体阳性与抑郁、言语记忆差、低IQ及随访功能差相关。
  • NMDAR抗体阳性并未预示后续精神病转化,但可能与杏仁核体积增大相关。

核心结论

  • NMDAR自身抗体在部分CHR个体中可检测到,阳性率与健康对照相当。
  • 在CHR组内,NMDAR抗体与情感性精神病理、言语记忆和整体认知功能损害相关。
  • NMDAR抗体状态与随访时功能较差及杏仁核体积较大相关,但与后续精神病转化无关。

研究设计与样本

  • 病例对照研究,纳入254例临床高危(CHR)精神病个体和116名健康志愿者。
  • 使用固定和活细胞基于的检测法(CBA)检测针对多种神经元抗原的抗体。
  • 在CHR组内分析NMDAR抗体与症状、认知功能及24个月随访临床结局的关系。

主要发现

  • CHR个体神经元自身抗体血清阳性率不高于对照(8.3% vs. 5.2%;OR=1.50;95%CI: 0.58-3.90)。
  • NMDAR是最常见的靶抗原,活细胞CBA比固定CBA更敏感地检测NMDAR IgG(p<0.001)。
  • CHR样本中,NMDAR抗体血清阳性者当前抑郁水平更高,Rey听觉言语学习任务表现更差(p<0.05),IQ显著更低(p<0.01)。
  • NMDAR IgG在后来转为精神病者中并不比未转者更常见。
  • NMDAR抗体血清状态和滴度与随访时功能较差相关(p<0.05),神经元自身抗体存在与杏仁核体积较大相关(p<0.05)。

关键数值与推荐

  • CHR组与对照组血清阳性率比较:8.3% vs. 5.2%;OR=1.50;95%CI: 0.58-3.90。
  • 活细胞与固定CBA检测NMDAR IgG敏感性比较:p<0.001。
  • NMDAR抗体阳性与言语记忆任务表现差异:p<0.05。
  • NMDAR抗体阳性与IQ差异:p<0.01。
  • NMDAR抗体状态与随访功能水平关联:p<0.05;神经元自身抗体与杏仁核体积关联:p<0.05。

临床怎么用

  • 对CHR个体可考虑检测NMDAR抗体以识别具有情感症状和认知损害亚型的个体。
  • NMDAR抗体阳性不能作为预测精神病转化的生物标志物,但可能与随访功能较差相关。
  • 检测NMDAR抗体时活细胞CBA可能比固定CBA更敏感。

局限性

  • 表型分析为初步探索性,样本量有限。
  • NMDAR抗体与临床特征和结局的关联需进一步验证。
  • 研究未明确抗体检测在CHR人群中的常规临床应用价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serum neuronal autoantibodies, such as those to the NMDA receptor (NMDAR), are detectable in a subgroup of patients with psychotic disorders. It is not known if they are present before the onset of psychosis or whether they are associated with particular clinical features or outcomes. In a case-control study, sera from 254 subjects at clinical high risk (CHR) for psychosis and 116 healthy volunteers were tested for antibodies against multiple neuronal antigens implicated in CNS autoimmune disorders, using fixed and live cell-based assays (CBAs). Within the CHR group, the relationship between NMDAR antibodies and symptoms, cognitive function and clinical outcomes over 24 month follow-up was examined. CHR subjects were not more frequently seropositive for neuronal autoantibodies than controls (8.3% vs. 5.2%; OR = 1.50; 95% CI: 0.58-3.90). The NMDAR was the most common target antigen and NMDAR IgGs were more sensitively detected with live versus fixed CBAs (p < 0.001). Preliminary phenotypic analyses revealed that within the CHR sample, the NMDAR antibody seropositive subjects had higher levels of current depression, performed worse on the Rey Auditory Verbal Learning Task (p < 0.05), and had a markedly lower IQ (p < 0.01). NMDAR IgGs were not more frequent in subjects who later became psychotic than those who did not. NMDAR antibody serostatus and titre was associated with poorer levels of functioning at follow-up (p < 0.05) and the presence of a neuronal autoantibody was associated with larger amygdala volumes (p < 0.05). Altogether, these findings demonstrate that NMDAR autoantibodies are detectable in a subgroup of CHR subjects at equal rates to controls. In the CHR group, they are associated with affective psychopathology, impairments in verbal memory, and overall cognitive function: these findings are qualitatively and individually similar to core features of autoimmune encephalitis and/or animal models of NMDAR antibody-mediated CNS disease. Overall the current work supports further evaluation of NMDAR autoantibodies as a possible prognostic biomarker and aetiological factor in a subset of people already meeting CHR criteria.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pollak TA, Kempton MJ, Iyegbe C, et al. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Mol Psychiatry. 2020. PMID: 33077853. doi:10.1038/s41380-020-00899-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。